1. Show article details.

    Why SpringWorks Shares Are Soaring Today Premarket

    Benzinga – 8:29 AM ET 05/24/2022

    Why SpringWorks Shares Are Soaring Today Premarket

  2. Show article details.

    The Daily Biotech Pulse: INmune Bio's Planned Alzheimer's Trial On FDA Hold, Caladrius Stops Enrollment In Heart Disease Study, BiomX Restructures

    Benzinga – 8:24 AM ET 05/24/2022

    Here's a roundup of top developments in the biotech space over the last 24 hours: The FDA has requested additional information on the Chemistry Manufacturing and Controls of the newly manufactured INmune Bio Inc's  XPro1595. As part of the communication, the FDA placed the company's Investigational New Drug application for the Phase 2 trial of XPro in Alzheimer's Disease on clinical hold.

  3. Show article details.

    AbbVie Showcases its Leadership in Rheumatology Research with New Data Across Multiple Inflammatory Joint Diseases at the EULAR 2022 Congress

    PR Newswire – 8:00 AM ET 05/24/2022

    - SELECT-AXIS 2 highlights the efficacy and safety data of upadacitinib in patients with non-radiographic axial spondyloarthritis, and in patients with radiographic axial spondyloarthritis with an inadequate response to biologic disease-modifying antirheumatic drugs- SELECT-PsA 1 & 2 highlight the efficacy and safety data of RINVOQ at two years in psoriatic arthritis patients with an inadequate...

  4. Show article details.

    If You Invested $1000 In AbbVie 5 Years Ago, Here's How Much You Would Have Today

    Benzinga – 4:02 PM ET 05/23/2022

    AbbVie has outperformed the market over the past 5 years by 7.1% on an annualized basis producing an average annual return of 17.45%. Currently, AbbVie has a market capitalization of $260.97 billion. Buying $1000 In ABBV: If an investor had bought $1000 of ABBV stock 5 years ago, it would be worth $2,226.33 today based on a price of $147.68 for ABBV at the time of writing.

  5. Show article details.

    Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2022

    Benzinga – 10:33 AM ET 05/23/2022

      See all analyst ratings upgrades.   See all analyst ratings downgrades.   See all analyst ratings initiations.

  6. Show article details.

    What 8 Analyst Ratings Have To Say About AbbVie

    Benzinga – 9:05 AM ET 05/23/2022

    Within the last quarter, AbbVie has observed the following analyst ratings: According to 8 analyst offering 12-month price targets in the last 3 months, AbbVie has an average price target of $169.38 with a high of $200.00 and a low of $140.00. Below is a summary of how these 8 analysts rated AbbVie over the past 3 months. This average price target has increased by 11.75% over the past month.

  7. Show article details.

    BRIEF-Abbvie Presents Positive Data From Phase 3 Study Of Major Depressive Disorder Treatment

    Reuters – 8:49 AM ET 05/23/2022

    Abbvie Inc (ABBV): * ABBVIE PRESENTS POSITIVE DATA FROM PHASE 3 STUDY OF CARIPRAZINE FOR THE ADJUNCTIVE TREATMENT OF MAJOR DEPRESSIVE DISORDER AT 2022 APA ANNUAL MEETING Source text for Eikon: Further company coverage:

  8. Show article details.

    AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting

    PR Newswire – 8:00 AM ET 05/23/2022

    NORTH CHICAGO, Ill. AbbVie's (ABBV) supplemental New Drug Application for cariprazine was supported by two positive registration-enabling studies, of which one was Study 3111-301-001.

  9. Show article details.

    EMA's CHMP Recommends AbbVie's Upadacitinib For Ulcerative Colitis

    Benzinga – 7:01 AM ET 05/23/2022

    EMA's CHMP Recommends AbbVie's Upadacitinib For Ulcerative Colitis

  10. Show article details.

    BRIEF-AbbVie Inc Says CHMP Recommends European Commission Approval Of Upadacitinib For Treatment Of Adults With Moderate To Severe Ulcerative Colitis

    Reuters – 2:05 AM ET 05/23/2022

    Abbvie Inc (ABBV): * CHMP RECOMMENDS EUROPEAN COMMISSION APPROVAL OF UPADACITINIB FOR THE TREATMENT OF ADULTS WITH MODERATE TO SEVERE ULCERATIVE COLITIS. * CHMP POSITIVE OPINION IS BASED ON RESULTS FROM THREE PHASE 3 STUDIES: TWO FOR INDUCTION AND ONE FOR MAINTENANCE. * IF APPROVED BY EUROPEAN COMMISSION, THIS WOULD BE UPADACITINIB'S FIFTH THERAPEUTIC INDICATION IN EU.

  11. Show article details.

    CHMP Recommends European Commission Approval of Upadacitinib (RINVOQ®) for the Treatment of Adults with Moderate to Severe Ulcerative Colitis

    PR Newswire – 2:00 AM ET 05/23/2022

    NORTH CHICAGO, Ill.

  12. Show article details.

    CNBC's Final Trades: AbbVie, Costco Wholesale, Deere And This Kevin O'Leary Pick

    Benzinga – 4:22 PM ET 05/22/2022

    On CNBC's "Halftime Report Final Trades," Kevin O'Leary, known as "Mr. Wonderful," said that consumer goods, especially baby powder and baby formula, have been "in the news lately." O'Leary added, "Nestle is a great trade name" and a global behemoth, with 50% of its sales in the US.

  13. Show article details.

    The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More

    Benzinga – 3:58 PM ET 05/22/2022

    Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The spread of the monkey pox virus in the U.S. and Europe sparked a rally in companies working on vaccine candidates against viruses. NanoViricides, Inc. also advanced strongly following positive clinical updates provided by the company.

  14. Show article details.

    Kessler Topaz Meltzer & Check, LLP Reminds Investors of June 6, 2022 Deadline in Securities Fraud Class Action against AbbVie, Inc. and Urges Investors with Substantial Losses to Contact the Firm

    GlobeNewswire – 6:55 PM ET 05/21/2022

    The law firm of Kessler Topaz Meltzer & Check, LLP informs investors that the firm has filed a securities class action lawsuit in the United States District Court for the Northern District of Illinois against AbbVie, Inc. (ABBV) on behalf of all persons and entities who purchased or otherwise acquired AbbVie (ABBV) securities between April 30, 2021, and August 31, 2021, inclusive.

  15. Show article details.

    AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

    Benzinga – 3:06 PM ET 05/20/2022

    AbbVie Submits FDA Application For Continuous, 24-Hour Infusion Therapy For Parkinson's

  16. Show article details.

    9 Stocks Moved By Traders On 'Fast Money: Halftime Report'

    Benzinga – 2:28 PM ET 05/20/2022

    CNBC's "Fast Money: Halftime Report" delivers market-moving news to investors. The commentary delivered by hosts of the show often moves the stocks mentioned. Kevin O'Leary of "Shark Tank" bought shares in the following companies: Cognex Corporation Shannon Saccocia of SVB Private said she sold her position in Cognex, citing underperformance in the stock.

  17. Show article details.

    BRIEF-AbbVie Submits New Drug Application To FDA For Investigational ABBV-951 For Treatment Of Advanced Parkinson's Disease

    Reuters – 8:44 AM ET 05/20/2022

    Abbvie Inc (ABBV): * ABBVIE SUBMITS NEW DRUG APPLICATION TO U.S. FDA FOR INVESTIGATIONAL ABBV-951 FOR THE TREATMENT OF ADVANCED PARKINSON'S DISEASE. * Abbvie Inc (ABBV) - WILL CONTINUE TO PURSUE REGULATORY SUBMISSIONS FOR ABBV-951 ACROSS INTERNATIONAL MARKETS THROUGHOUT YEAR Source text for Eikon: Further company coverage:

  18. Show article details.

    AbbVie Submits New Drug Application to U.S. FDA for Investigational ABBV-951 (Foscarbidopa/Foslevodopa) for the Treatment of Advanced Parkinson's Disease

    PR Newswire – 8:15 AM ET 05/20/2022

    NORTH CHICAGO, Ill. The submission is based on results from a Phase 3, head-to-head, randomized and controlled clinical trial demonstrating statistically significant improvement in "On" time without troublesome dyskinesia compared to oral immediate-release carbidopa/levodopa. ABBV-951 is designed to provide a first-of-its-kind, 24-hour, continuous subcutaneous delivery of CD/LD.

  19. Show article details.

    AbbVie Whale Trades Spotted

    Benzinga – 4:32 PM ET 05/19/2022

    Someone with a lot of money to spend has taken a bullish stance on AbbVie. And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know. So how do we know what this whale just did?

  20. Show article details.

    ABBV LAWSUIT ALERT: Levi & Korsinsky Notifies AbbVie Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

    PR Newswire – 2:00 PM ET 05/19/2022

    NEW YORK, May 19, 2022 Levi & Korsinsky, LLP notifies investors in AbbVie Inc. (ABBV) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of AbbVie (ABBV) investors who were adversely affected by alleged securities fraud between April 30, 2021 and August 31, 2021.

Page:

Today's and Upcoming Events

  • Jul
    28

    ABBV to announce Q2 earnings (Unconfirmed)

Past Events (last 90 days)

  • Apr
    29

    ABBV announced Q1 earnings.

  • Apr
    13

    ABBV ex-Dividend for $1.41 on 04/13/2022

    • Announce Date: 02/17/2022
    • Record Date: 04/15/2022
    • Pay Date: 05/16/2022
Data provided by Thomson Reuters © 2022

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.